FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Section	on 30(	(n) of the	Investm	ent C	ompany Act	of 1940							
Name and Address of Reporting Person*     Wingrove Theresa						2. Issuer Name <b>and</b> Ticker or Trading Symbol ImmunoGen, Inc. [ IMGN ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner					
(Last)	(F MUNOGEN	,	(Middle)			Date o /15/2		iest Trans	saction (	Month	n/Day/Year)		X Officer (give title Other (specify below) below)  SVP OF REGULATORY AFFAIRS						
830 WINTER STREET					4.1	f Ame	ndme	nt, Date o	of Origin	al File	ed (Month/Da	Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(Street) WALTH	AM M	ΙA	02451			Form filed by More than One Reporting Person													
(City)	(S	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to													
		Tok	ula I. Ni	an Davis		satis	fy the a	affirmative	defense	condit	ions of Rule 1	.0b5-1(c). Se	e Instructio	n 10.					
		Tab	ne i - No	on-Deri	vativ	e Se	curit	ies Ac	quirec	ı, Di	sposed o	π, or Be	петісіаі	y Owned	l				
''''''''			2. Transaction Date (Month/Day/Year		Executio		xecution Date, any		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			(111511. 4)	
Common Stock			09/15	9/15/2023				M		50,000	A	\$4.55	136	136,156		D			
Common Stock			09/15	09/15/2023				M		33,334	A	\$3.05	169	169,490		D			
Common Stock 09/15				2023				M		25,334	A	\$2.68	194	194,824		D			
Common Stock 09/15/2				/2023	2023			S		192,013	B D	\$15.44	2,811			D			
		-	Table II						,		oosed of, converti		•	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executio			Transaction Code (Instr.				Exerc ion Da Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$4.55	09/15/2023			M			50,000	(2)		02/07/2030	Common Stock	50,000	\$0	241,76	69	D		
Stock Option (right to buy)	\$3.05	09/15/2023			М			33,334	(3)		07/18/2026	Common Stock	33,334	\$0	16,660	6	D		

## **Explanation of Responses:**

\$2.68

Stock Option (right to

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.30 to \$15.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

(4)

2. On 2/7/2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. As of the transaction date, 75% of the awarded options are vested.

25,334

3. This option was granted on 7/18/2016 and is fully vested as of the transaction date.

09/15/2023

4. This option was granted on 9/30/2016 and is fully vested as of the transaction date.

/s/ Renee Lentini, Attorney-in-

25,334

\$0

09/19/2023

12,666

D

<u>Fact</u>

Commo

09/30/2026

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

M

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.